What's in Xiang Guang-da's pipeline?

Xiang Guang-da has 4 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with Xiang Guang-da's portfolio?

Top competitors by shared drug class: Bristol-Myers Squibb, Daewoong Pharmaceutical Co. LTD., Elcelyx Therapeutics, Inc., Eli Lilly and Company, Ente Ospedaliero Ospedali Galliera.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/xiang-guang-da.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Xiang Guang-da — Portfolio Competitive Intelligence Brief

Xiang Guang-da pipeline: 1 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
metformin 0.85 twice daily for 6 months	metformin 0.85 twice daily for 6 months	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase	Diabetes

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bristol-Myers Squibb · 1 shared drug class
Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
Elcelyx Therapeutics, Inc. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Ente Ospedaliero Ospedali Galliera · 1 shared drug class
First Affiliated Hospital of Wenzhou Medical University · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
AstraZeneca · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Xiang Guang-da:

Cite this brief

Drug Landscape (2026). Xiang Guang-da — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xiang-guang-da. Accessed 2026-05-16.